Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 3/20 | 0.61 |
| ▸ | TRDMT1 | O14717 | 5/20 | 0.48 |
| ▸ | WDR5 | P61964 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | RBBP5 | Q15291 | 2/20 | 0.46 |
| ▸ | DPY30 | Q9C005 | 2/20 | 0.46 |
| ▸ | ASH2L | Q9UBL3 | 2/20 | 0.46 |
| ▸ | NNMT | P40261 | 6/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.40 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16256998 | 0.84 | EZH2 (0.61) | EZH2TRDMT1WDR5KMT2ARBBP5 | |
| SCHEMBL18609767 | 0.84 | EZH2 (0.61) | EZH2TRDMT1WDR5KMT2ARBBP5 | |
| SCHEMBL15281887 | 0.76 | EZH2 (1.00) | EZH2TRDMT1WDR5KMT2ARBBP5 | |
| SCHEMBL17484640 | 0.76 | EZH2 (1.00) | EZH2TRDMT1WDR5KMT2ARBBP5 | |
| SCHEMBL20612160 | 0.76 | EZH2 (1.00) | EZH2TRDMT1WDR5KMT2ARBBP5 | |
| SCHEMBL469241 | 0.76 | EZH2 (1.00) | EZH2TRDMT1WDR5KMT2ARBBP5 | |
| SCHEMBL18609673 | 0.76 | EZH2 (1.00) | EZH2TRDMT1WDR5KMT2ARBBP5 | |
| SCHEMBL14706086 | 0.76 | EZH2 (1.00) | EZH2TRDMT1WDR5KMT2ARBBP5 | |
| SCHEMBL21338044 | 0.76 | EZH2 (0.79) | EZH2TRDMT1WDR5KMT2ARBBP5 | |
| SCHEMBL805652 | 0.76 | EZH2 (0.91) | EZH2TRDMT1WDR5KMT2ARBBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071418-A1 | Inhibitors of Human EZH2 and Methods of Use Thereof | Epizyme, Inc. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071418-A1 | Inhibitors of Human EZH2 and Methods of Use Thereof | EZH2, DOT1L, PRDM7 | EZH2 1/4885TRDMT1 147/4885WDR5 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.